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RESULTS: Within 2 years of incision, excision and anas-
tomosis of intestine, 14.3% of patients had obstruction,
2.6% required an adhesiolysis for obstruction, and
12.9% underwent additional open colorectal or general
surgery. After other operations of intestine, 17% of pa-
tients had obstruction, 3.1% required an adhesiolysis,
and 20.2% underwent additional surgery. After opera-
tions of rectum, rectosigmoid and perirectal tissue, 15.3%
of patients had obstruction, 5.1% required an adhesioly-
sis, and 16.4% underwent additional surgery.
CONCLUSIONS: In this study of Medicare patients,
bowel obstruction, adhesiolysis for obstruction, and ad-
ditional abdominal surgery occurred more often after ab-
dominal surgery than previously published.
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OBJECTIVE: To compare the effectiveness and costs of
care for nifedipine-CC and amlodipine when used for ini-
tial management of uncomplicated hypertension.
METHODS: A retrospective analysis was conducted us-
ing outpatient pharmacy, provider, and hospital dis-
charge claims records of continuously eligible Pennsylva-
nia Medicaid patients started on either drug in 1994
without prescriptions for other anti-hypertensive agents
or reported cardiovascular complications in the 8 months
prior to initial nifedipine-CC or amlodipine prescription.
Comparison of three indicators of change in prescrip-
tions were evaluated to provide information on medica-
tion effectiveness. Chi-square tests of association were
conducted to evaluate effectiveness indicators while lin-
ear regression was utilized to compare costs.
RESULTS: Patients satisfying inclusion/exclusion crite-
ria who received nifedipine-CC (n  151) or amlodipine
(n  316) had similar demographic characteristics and
levels of comorbidity. A slightly greater percentage of pa-
tients started on nifedipine-CC had prescription records
consistent with cross-over to a different calcium channel
blocker (15.3% versus 10.3%) while a greater percentage
of patients started on amlodipine had records consistent
with cross-over to another class of anti-hypertensive
agent (7.3% versus 13.2%). In adherent patients, other
anti-hypertensive drugs were added to each regimen to a
similar extent and no differences were found in adverse
events that were reported. Total pharmacy costs were de-
termined to be significantly higher (p  0.0001) in pa-
tients started on amlodipine ($2536 higher in patients
with the most comorbidity to $293 in the least).
CONCLUSIONS: The results suggest these drugs have
similar effectiveness and that physicians’ drug preferences
can have important effects on total pharmacy costs.
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OBJECTIVE: The purpose of this study is to evaluate the
cost-effectiveness of the immunosuppressive regimen, cy-
closporine, mycophenolate mofetil, and prednisone (CMP),
in improving 3-year graft survival in kidney transplant re-
cipients as compared to the immunosuppressive regimen,
cyclosporine, azathioprine, and prednisone (CAP).
METHODS: A sample of kidney transplant recipients re-
ceiving either cadaveric or living donor transplants in
1996 was selected from the United States Renal Data Sys-
tem (USRDS). Direct costs were estimated from Medicare
reimbursements and included: outpatient costs, hospital-
ization costs due to rejection episodes, infectious compli-
cations, or graft failure, dialysis costs due to graft failure,
and medication costs. The effectiveness measure was
length of graft survival and expressed as the total number
of life-months with an intact graft. A Markov model in-
cluding three Markov states (e.g., graft intact, return to
dialysis as a result of graft failure, and death) and two
transient states (e.g., graft rejection and complications)
was used to model the course of progression and continu-
ous risk of graft rejection. The USRDS data were also
used to estimate transplant recipients’ transition proba-
bilities throughout the Markov stages.
RESULTS: Although mycophenolate mofetil costs sub-
stantially more than azathioprine ($6000 versus $1000
annually), preliminary findings suggest that the CMP reg-
imen is more cost-effective than CAP because of the re-
duction in hospitalizations and treatment costs saved by
avoiding acute graft rejection episodes.
CONCLUSIONS: Our study provides valuable informa-
tion regarding the most cost-effective immunosuppressive
regimen to renal transplant centers. Findings from this
study will also be of interest to the Medicare End-Stage
Renal Disease (ERSD) program since a majority of the kid-
ney transplant patients were covered under this program.
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OBJECTIVE: To use data from the HCIA hospital claims
database to track pharmaceutical use, incidence of ad-
verse events, and costs in patients undergoing PCI.
METHODS: We analyzed hospital claims data from a
nationally representative sample of 11,086 patients who
underwent PCI between October 1996 and September
1997 to determine inpatient pharmaceutical use, patient
outcomes (i.e., repeat PCI, coronary artery bypass sur-
gery [CABG], or death), the incidence of adverse events
(i.e., bleeding), and costs. Analyses were conducted using
a multivariate model to control for patient severity and
other exogenous factors, yielding conservative and upper
bound cost estimates.
RESULTS: Mean total heparin dosage was approxi-
mately 83,000 units per patient per hospital stay. Stents
and abciximab were used in 51% and 21% of patients,
respectively. CABG was necessary in 2.4% of patients
and repeat procedure in more than 5.5% of patients; the
incidence of death was 1.5%. Bleed rates (defined as any
patient receiving a red blood cell transfusion) was 6.3%
throughout the study period with 5.1% of patients re-
quiring a transfusion of two or more units. Even among
non-CABG patients, bleed rates were nearly 5%. Cost for
an uncomplicated PTCA averaged $9555. The incremen-
tal cost for managing patients who suffered an adverse
outcome or event averaged $5745. A less conservative
model incorporating increased length of hospital stay
showed that the average patient with complications in-
curred additional costs of $11,780.
CONCLUSION: Hospital claims databases are a cost-
effective alternative for tracking the costs and outcomes
associated with inpatient pharmaceutical use. In the case
of PCI, hospital claims data offers the ability to track re-
peat procedure, CABG, death, and bleeding rates as well
as costs.
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OBJECTIVE: To compare healthcare use and drug utili-
zation in patients with migraine and patients without mi-
graine headaches.
DESIGN: Retrospective review of Idaho Medicaid claims
database for claims filed during 1993 and during 1997.
METHODS: Inclusion criteria for the migraine patients
were: above the age of 4, with a migraine diagnosis and
one or more prescriptions for migraine medication, en-
rolled in Medicaid during 1993 and in 1997 (n  430).
The control group (n  1720) had to have at least one
non-migraine-related diagnosis and one or more prescrip-
tions during the study period for inclusion. A control
group was matched by age, gender, and geographic re-
gion. A 4:1 match was performed. Use of health services
and drug utilization in four identified treatment settings
and associated costs were compared between the mi-
graineurs and control group before and after removing
migraine-related costs. Differences in costs and utiliza-
tion of calcium-channel-blockers, anti-depressants, anal-
gesics, anti-migraine preparations, beta-blockers and
NSAIDs were analyzed separately.
RESULTS: Significant differences (p  0.05) in costs, in
all four treatment settings, number of procedures and vis-
its and drug utilization were found in both the years (viz.,
1993 and 1997) between the two groups, before and af-
ter removing migraine-related costs. After removing mi-
graine-related services and drugs used specifically for mi-
graine, the number of encounters, procedures in ERs,
physicians’ office, “unknown” setting, and utilization of
analgesics, beta-blockers and NSAIDs remained signifi-
cantly higher in migraineurs, in both years. Utilization of
narcotics was found to be nine times more among mi-
graineurs in 1993 and five times more in 1997.
CONCLUSION: Except for hospital outpatient services,
migraineurs use healthcare services more than a matched
comparison group even after removing migraine-related
costs.
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OBJECTIVE: Post-acute coronary syndrome (post-ACS)
patients experience very different survival patterns during
the acute and chronic phases of their illness. To provide a
clinically relevant life expectancy estimate for post-ACS
patients and subgroups of unstable angina (UA) and re-
cent (6 week) myocardial infarction (MI) patients, we
developed a two-component survival model which ac-
counted for differences in acute and chronic survival and
also extrapolated beyond the available follow-up data.
METHODS: We included UA and MI patients who re-
ceived an initial coronary angiography (cath) at Duke
University Medical Center between March 1984 and De-
cember 1997. Patients with previous cardiac procedures
or valvular disease were excluded. We defined the acute
post-ACS phase as lasting from the initial cath through 1
year follow-up and chronic phase as the second follow-
up year through end of life.
RESULTS: Our population contained 10,398 patients
with 12-year follow-up 95% complete. Initial treatment
strategy, age, body mass index, history of diabetes, cere-
bral or peripheral vascular disease, and congestive heart
failure were predictive of both acute and chronic phase
survival (p  0.05). Recent MI and year of initial cath
were predictive of acute phase survival whereas history of
MI and smoking were predictive of chronic phase sur-
vival (p  0.05). While acute phase mortality was greater
